CDC Firings Fray Lifelines to Local Health Departments

The U.S. public health system has long been under strain, stymied by declines in funding as well as employees. And so state and local public health departments around the nation — tasked with monitoring and responding to disease outbreaks that threaten to sicken the masses — have relied on workers from the Centers for Disease…

Read More

A Backlash Against Health Insurers, Redux

In this JAMA Health Forum post, Executive Vice President Larry Levitt recalls the mid-1990s’ public backlash against Health Maintenance Organizations (commonly known as HMOs) – all of which preceded the recent outpouring of health insurance concerns – as well as how consumer protections against coverage restrictions have evolved and fallen short.

Read More

Consequences of Tariffs on Pharmaceutical Products

That is the topic of a JMCP Viewpoint by Sean Sullivan, Jens Grueger, Aidan Sullivan, and Scott Ramsey. Some excerpts: The Budget Lab at Yale University projected that a 25% ad valorem tariff would increase medication costs by an “average of around $600 per year per household in the United States.”3 Tariffs can also create supply…

Read More

BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease

Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition…

Read More